About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Quetzal Therapeutics Appoints Dr. Shaad Abedin as Chief Medical Officer

CHICAGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing transformative therapies for patients with rare and life-threatening diseases, today announced the appointment of Dr. Shaad Abedin as Chief Medical Officer.

Dr. Abedin brings to Quetzal extensive experience in oncology drug development, translational medicine, biomarker strategy, and business development. He has a proven track record of advancing groundbreaking therapies across multiple modalities and leading clinical programs from early development through global regulatory approvals.

Most recently, Dr. Abedin served as Senior Vice President and Head of Clinical Development at iTeos Therapeutics, where he oversaw clinical development and clinical pharmacology for a pipeline spanning both small- and large-molecule programs. Prior to iTeos, he held senior leadership roles at CARsgen and Immunocore, where he directed the clinical development of tebentafusp (KIMMTRAK®), the first TCR bispecific therapy to achieve worldwide approval.

Earlier in his career, Dr. Abedin held positions at AstraZeneca/MedImmune, contributing to the early development of checkpoint inhibitors durvalumab (Imfinzi®) and tremelimumab (Imjudo®). He has submitted multiple INDs and led development efforts across biologics, antibodies, mRNA therapies, ADCs, CAR-T, and small molecules. In addition, he has played a key role in forging strategic alliances and partnerships to accelerate novel therapeutics.

Dr. Abedin is widely published, with more than 80 scientific works and patents, including publications in leading journals such as The New England Journal of Medicine, Nature, Journal of Clinical Oncology, and Annals of Oncology.

“We are thrilled to welcome Dr. Abedin to Quetzal at this pivotal stage of our growth,” says Usman Ahmed, Chief Executive Officer and Chairman of Quetzal Therapeutics. “His deep expertise in oncology and proven leadership will not only strengthen our clinical development capabilities but also help shape the partnerships and strategies that will drive our long-term growth.”

Dr. Abedin completed his residency in internal medicine at the University of Texas Medical Branch in Galveston, Texas, followed by a fellowship in hematology and medical oncology at the Albert Einstein College of Medicine in New York. He is U.S. board certified in internal medicine, hematology, and medical oncology.

Strategic Talent Acquisition Partnership
Quetzal Therapeutics proudly recognizes Heidrick & Struggles, a leading global leadership advisory firm, for their pivotal role in identifying and recruiting Dr. Shaad Abedin to Quetzal Therapeutics. Their deep expertise and commitment to excellence were instrumental in bringing on a highly respected leader whose insights will help guide Quetzal’s long-term scientific vision and clinical strategy.

About Quetzal Therapeutics
Quetzal Therapeutics is a biopharmaceutical company focused on the development of treatment for rare diseases including hematologic malignancies. The company’s lead product is QTX-2101, a novel paradigm for treating patients with Acute Promyelocytic Leukemia (APL). The company plans to initiate Phase III clinical trials by late-2025, with enabling activities ongoing. Quetzal is also developing a pre-clinical asset QTX-2102, an advanced, next-generation antifungal and antiparasitic therapy designed to enhance efficacy while minimizing toxicity. Learn more at quetzaltx.com.

Media Contact:
media@quetzaltx.com


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.